Key terms
About AQST
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AQST news
Apr 11
5:11am ET
Aquestive Therapeutics initiated with an Overweight at Piper Sandler
Apr 05
6:30am ET
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
Apr 03
5:29pm ET
Aquestive Therapeutics files $250M mixed securities shelf
Apr 01
8:33am ET
Aquestive Therapeutics Welcomes Abigail Jenkins to Board
Apr 01
8:17am ET
Aquestive Therapeutics appoints Jenkins to board of directors
Mar 27
4:26pm ET
Aquestive Therapeutics initiated with an Outperform at Raymond James
Mar 20
6:35am ET
Aquestive Therapeutics 16.667M share Spot Secondary priced at $4.50
Mar 19
4:04pm ET
Aquestive Therapeutics announces common stock offering, no amount given
Mar 18
6:26am ET
Buy Rating Affirmed for Aquestive Therapeutics on Strong Phase 3 Results for Anaphylm™ with Raised Price Target
Mar 18
6:14am ET
Aquestive Therapeutics price target raised to $9 from $7 at H.C. Wainwright
Mar 15
6:11am ET
Aquestive Therapeutics price target raised to $10 from $8 at JMP Securities
Mar 14
5:33pm ET
Aquestive Therapeutics’ Anaphylm meets endpoints in Phase 3 allergy study
Mar 11
6:15am ET
Aquestive Therapeutics price target raised to $7 from $6 at H.C. Wainwright
Mar 07
8:52am ET
Aquestive Therapeutics price target raised to $8 from $3 at Lake Street
Mar 07
8:50am ET
Analysts Offer Insights on Healthcare Companies: Viemed Healthcare (VMD) and Aquestive Therapeutics (AQST)
Mar 06
12:45pm ET
Reiterating Outperform Rating on Aquestive: Buy Recommendation Amid Promising Anaphylm Developments and Strategic Market Positioning
Mar 06
10:57am ET
Buy Rating Affirmed for Aquestive Therapeutics Amid Strong Pipeline and Market Potential
Mar 05
5:23pm ET
Aquestive Therapeutics Updates Investors with Presentation and Financials
Mar 05
3:04pm ET
Aquestive Therapeutics options imply 25.7% move in share price post-earnings
Mar 05
7:05am ET
Options Volatility and Implied Earnings Moves Today, March 05, 2024
Feb 15
9:15am ET
Buy Rating Affirmed for Aquestive Therapeutics Amidst PharmFilm Progress and Anticipated Clinical Milestones
Feb 15
8:18am ET
Aquestive Therapeutics announces presentation on Anaphylm PK, PD data
No recent press releases are available for AQST
AQST Financials
Key terms
Ad Feedback
AQST Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AQST Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
